| Statistical and Computation Methods for Cancer Early Detections |
Yunro Chung |
Arizona Board of Regents for and on behalf of Arizona State University |
PLCO |
Nov 6, 2026 |
PLCO-2095 |
| Serum concentrations of per- and polyfluoroalkyl substances and testicular cancer risk: A nested case-control study within the Military Aviators Cancer Study |
Mark Purdue |
National Cancer Institute |
MACS |
Nov 4, 2026 |
2026-0144 |
| Profiling the malignant melanoma sites and melanoma for 25 years of DoW pilots and aircrew. |
Bradley Williams |
60 MDG Clinical Investigation |
MACS |
Nov 4, 2026 |
2026-0132 |
| PILOT 96 samples from prior HCC study to Nomic |
Steven Moore |
NCI |
PLCO |
Oct 26, 2026 |
2027-0218 |
| Open and reproducible thoracic CT phenotypic age for mortality risk in the National Lung Screening Trial |
Kin Meng Eric Fang |
National University Hospital (Singapore) Pte Ltd |
NLST |
Oct 12, 2026 |
NLST-1530 |
| Early Lung Nodule Malignancy Assessment Using Longitudinal Chest CT Data |
Toru Higaki |
Hiroshima University |
NLST |
Oct 12, 2026 |
NLST-1534 |
| Developing a multimodal foundation model integrating NLST CT and H&E images for improved lung cancer diagnosis |
Nancy Guo |
SUNY Binghamton University |
NLST |
Oct 12, 2026 |
NLST-1538 |
| Outcomes of men aged ≥60 years old with moderately elevated PSA (1–20 ng/mL) in the PLCO cancer screening trial |
Scott Eggener |
University of California, Los Angeles |
PLCO |
Oct 5, 2026 |
PLCO-2084 |
| Plasma-Volume–Adjusted PSA Density for Detection of Clinically Significant Prostate Cancer in the PLCO Trial (Original Project: PLCO-2070)) |
Firas Abdollah |
Henry Ford Health |
PLCO |
Oct 5, 2026 |
PLCO-2086 |
| Quantitative CT Imaging Measures and Clinical Risk Factors for Airflow Obstruction in a Lung Cancer Screening Population |
Sabee Molloi |
The Regents of the University of California- Irvine |
NLST |
Oct 5, 2026 |
NLST-1536 |
| Machine-learning Modelling Gateways for Early-Disease Prediction of Lung Cancer |
Volker Hessel |
Adelaide University |
NLST |
Oct 5, 2026 |
NLST-1533 |
| Determinants of serum per- and polyfluoroalkyl substances (PFAS) in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial |
Rena Jones |
National Cancer Institute |
PLCO |
Sep 28, 2026 |
PLCO-2089 |
| Incidence of Upper Tract Urothelial Carcinoma in Relation to Smoking, Analgesic Use, and Medical History in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial |
Jonathan Hofmann |
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health |
PLCO |
Sep 28, 2026 |
PLCO-2085 |
| Quantitative Analysis of H&E Histopathology and Cancer Outcomes in PLCO |
James Kelley |
Pictor Labs. Inc. |
PLCO |
Sep 28, 2026 |
PLCOI-2081 |
| Contrastive Representation Learning for Efficient Lung Cancer Survival Prediction from CT Imaging |
Aldo Pacchiano Camacho |
Trustees of Boston University |
NLST |
Sep 28, 2026 |
NLST-1532 |
| Preliminary Evaluation and Comparative Analysis of Lung Cancer Risk Prediction Approaches Using NLST Low-Dose CT and Clinical Data |
Doyeon Lee |
Hecto |
NLST |
Sep 28, 2026 |
NLST-1526 |
| Plasma-Volume–Adjusted PSA Density for Detection of Clinically Significant Prostate Cancer in the PLCO Trial |
AKSHAY SOOD |
The Ohio State University |
PLCO |
Sep 28, 2026 |
PLCO-2070 |
| A nested case-control study of serum concentrations of per- and polyfluoroalkyl substances and thyroid cancer risk among military aviators and aviation support personnel |
Jonathan Hofmann |
National Cancer Institute |
MACS |
Sep 24, 2026 |
2026-0134 |
| Analytical Suitability and Storage-Stability Pilot for a Serum NMR-Based Multi-Omics Multi-Cancer Early Detection Assay Using Pre-Diagnostic PLCO Specimens |
PATRICK STRASSER |
Wholomics GmbH |
PLCO |
Sep 15, 2026 |
2026-0185 |
| The Population Attributable Fractions of Pancreatic Cancer Caused by Key Risk Factors (continuation of PLCO-351) |
Rachael Stolzenberg-Solomon |
NCI, NIH |
PLCO |
Sep 10, 2026 |
PLCO-2083 |
